Detalles de la búsqueda
1.
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.
Circulation
; 137(9): 961-972, 2018 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29483172
2.
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
Circulation
; 132(4): 302-61, 2015 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25547519
3.
Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.
Circulation
; 131(18): 1590-8, 2015 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25940966
4.
Troponin measurements during drug development--considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration.
Am Heart J
; 162(1): 64-73, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21742091
5.
Is randomization to placebo safe? Risk in placebo-controlled angina trials: angina risk meta-analysis.
Cardiology
; 120(3): 174-81, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22261892
6.
Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.
Am Heart J
; 159(5): 716-29, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20435178
7.
Electrocardiographic assessment for therapeutic proteins--scientific discussion.
Am Heart J
; 160(4): 627-34, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20934555
8.
Duchenne muscular dystrophy: Drug development and regulatory considerations.
Muscle Nerve
; 41(6): 740-5, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20373504
9.
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
J Nucl Cardiol
; 22(5): 1041-144, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26204990
10.
Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
Am Heart J
; 157(5): 827-36, 836.e1, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19376308
11.
Quantitative Understanding of QTc Prolongation and Gender as Risk Factors for Torsade de Pointes.
Clin Pharmacol Ther
; 103(2): 304-309, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29219167
12.
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.
J Am Coll Cardiol
; 71(9): 1021-1034, 2018 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29495982
13.
Bleeding Academic Research Consortium consensus report: the Food and Drug Administration perspective.
Circulation
; 123(23): 2664-5, 2011 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-21670240
14.
Acute heart failure syndromes: current state and framework for future research.
Circulation
; 112(25): 3958-68, 2005 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-16365214
15.
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards).
J Am Coll Cardiol
; 66(4): 403-69, 2015 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25553722
Resultados
1 -
15
de 15
1
Próxima >
>>